Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid
| Autor: | Masahiro Hatooka, Fumi Honda, Yohji Honda, Norihito Nakano, Yoshiiku Kawakami, Yuki Nakamura, Michio Imamura, Takayuki Fukuhara, Kei Morio, Kazuaki Chayama, Tomokazu Kawaoka, Hiroshi Aikata, Akira Hiramatsu, Tomoki Kobayashi, Yuko Nagaoki |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Multivariate analysis Hepatology Receiver operating characteristic business.industry Bone metastasis Retrospective cohort study medicine.disease Gastroenterology Surgery Bone remodeling 03 medical and health sciences 0302 clinical medicine Infectious Diseases Zoledronic acid 030220 oncology & carcinogenesis Internal medicine Hepatocellular carcinoma medicine 030211 gastroenterology & hepatology business Type I collagen medicine.drug |
| Zdroj: | Hepatology Research. 47:1053-1060 |
| ISSN: | 1386-6346 |
| Popis: | Aims We retrospectively analyzed the clinical outcome and prognostic parameters in patients with hepatocellular carcinoma (HCC) and bone metastases who had received treatment with zoledronic acid (ZOL). Methods Ninety-nine HCC patients with bone metastases who had been treated with ZOL were enrolled in this retrospective cohort study. We analyzed the prognostic factors, including serum N-telopeptide of type I collagen (NTX) levels, as bone metabolism markers. Results The median overall survival (OS) time was 11.5 months. Child–Pugh grade A (P = 0.004) and intrahepatic tumor stage (IHTS) T0–3 (P = 0.010) correlated significantly with favorable OS. In 46 patients with grade A and T0–3, receiver operating characteristic curve analysis defined 16 nmol BCE/L serum NTX as the cut-off level for median OS. Multivariate analysis identified baseline serum NTX |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text